Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
br Declaration of interest br Acknowledgments
2022-07-14

Declaration of interest Acknowledgments This work was financially supported by the National Natural Science Foundation of China (No. 31471615), the Introduction of Talent Research Start-up Fund of Anhui Polytechnic University (No. 2017YQQ017) and the Pre-research Project of National Natural Sc
-
In teleosts GR is expressed in almost every
2022-07-14

In teleosts, GR is expressed in almost every cell and regulates genes controlling development, metabolism, and immune response [17,18]. Several teleosts contain two GR genes, GR1 and GR2 [8]. Other groups have found only one GR in some species thus far, such as the Japanese flounder, brown trout, an
-
After the origin of the family
2022-07-14

After the origin of the family of genes for receptors for peptides similar to glucagon, the genes have not remained static. Not only have their sequences evolved, but also like peptides similar to glucagon (Irwin, 2001, Irwin, 2009, Irwin, 2012, Ng et al., 2010, Hwang et al., 2013), the numbers of g
-
Genetic disruption or pharmacologic inhibition of the
2022-07-14

Genetic disruption or pharmacologic inhibition of the hepatic glucagon pathway has invariably been shown to increase pancreatic α cell mass. This has been observed in glucagon receptor (GCGR) knockout (Gcgr−/−) mice (Gelling et al., 2003), glucagon knockout mice (Hayashi et al., 2009), prohormone co
-
Initially we carried out gap
2022-07-14

Initially, we carried out gap-FRAP experiments using the two-photon configuration of the confocal microscope. A SR101-positive astrocyte was targeted and a 5 × 5 μm square area was exposed to a laser illumination (5 flashes of 5 s each during 25 s). This procedure resulted in a bleaching of this ast
-
In the thoracic spinal cord neither glacial acetic acid
2022-07-14

In the thoracic spinal cord, neither glacial acetic Boceprevir nor HBO2 had an effect on nNOS expression or expression of the phosphorylated β3 subunit of the GABAA receptor. This result was not unexpected due to the preponderance of nociceptive signaling in the lumbar versus thoracic spinal cord.
-
It should be noted that the applied steered unfolding of
2022-07-14

It should be noted that the applied steered unfolding of the i-motif and G-quadruplex satisfies the conditions of Jarzynski inequality for computations of the free energy change. [41] However, in order to reproduce the free energy with an adequate quality a number of nonequilibrium unfolding transit
-
We next determined the selectivity profile of the most
2022-07-14

We next determined the selectivity profile of the most potent GPR40 agonists (4k–n) against other free fatty DMP 777 receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). FFA2 and FFA3 agonists have a preference in binding short-chain fatty acids while FFA1 and FFA4 have a higher affinity to medium-
-
So what makes a FFAR agonist
2022-07-14

So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept
-
br Acknowledgments We apologize for the omission of primary
2022-07-14

Acknowledgments We apologize for the omission of primary citations owing to space limitations. This work was supported by grants from National Natural Science Foundation of China (81772801 and 81472455 to C.D.), the Key Program of Zhejiang Provincial Natural Science Foundation (LZ17H160002 to C.D
-
br Experimental procedures br Results br Discussion This stu
2022-07-14

Experimental procedures Results Discussion This study demonstrates that the genetic disruption or pharmacological inhibition of FAAH completely prevented all manifestations of pain symptoms in an NTG-induced migraine animal model. Thus, FAAH disruption or blockade abolished the activation o
-
Here we showed that microinjection of
2022-07-14

Here we showed that microinjection of siRNA at the MII stage efficiently reduced endogenous EZH2 mRNA and protein. Although the percentage of cleaving embryos was not affected, Toremifene formation and blastocyst cell number were both reduced in EZH2 knockdown groups (Table 1). Similar results have
-
Recent studies have shown that epigenetic modification is in
2022-07-14

Recent studies have shown that epigenetic modification is involved in neuropathic pain. For instance, peripheral noxious stimulation changes DNA methylation and histone modifications, which are related to pain hypersensitivity under chronic pain conditions [8]. Importantly, the epigenetic abnormalit
-
Most hexokinases are widely expressed but distinct hexokinas
2022-07-14

Most hexokinases are widely expressed but distinct hexokinases predominate specific tissues (Katzen and Schimke, 1965, Rogers et al., 1975). Hexokinase I is found in all mammalian tissues, but is most abundant in the GSK1324726A and kidney (griffin et al., 1992). Hexokinase II is the primary hexoki
-
br Materials and methods br Author contributions br Acknowle
2022-07-14

Materials and methods Author contributions Acknowledgments We thank members of the Skaar laboratory for critical evaluation of the manuscript. This work was supported by grants from the National Institutes of Health, R01AI069233 (EPS), and T32GM008554-21 (LJL). Introduction Pseudomonas
14883 records 398/993 page Previous Next First page 上5页 396397398399400 下5页 Last page